BMO Capital Markets boosted their price target on shares of Applied Genetic Technologies Corp (NASDAQ:AGTC) from $21.00 to $34.00 in a research note issued on Monday. The firm currently has an “outperform” rating on the stock. BMO Capital Markets’ target price points to a potential upside of 34.44% from the stock’s previous close. Applied Genetic Technologies Corp (NASDAQ:AGTC) stock performance was 7.57% in last session and finished the day at $25.87. Traded volume was 94,898.00million shares in the last session and the average volume of the stock remained 76.15K shares. Applied Genetic Technologies Corp (NASDAQ:AGTC) insider ownership is %10.40.

Alder Biopharmaceuticals Inc (NASDAQ:ALDR) quiet period will end on Tuesday, June 17th. Alder Biopharmaceuticals had issued 8,000,000 shares in its IPO on May 8th, American Banking and Market News reports. The total size of the offering was $80,000,000 based on an initial share price of $10.00. During company’s quiet period, insiders and underwriters that worked on the IPO are restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Alder Biopharmaceuticals Inc (NASDAQ:ALDR) rose 7.29 percent to $18.70 Thursday on volume of 138,520.00million shares. The intra-day range of the stock was $17.12 to $19.49. Alder Biopharmaceuticals Inc (NASDAQ:ALDR) has a market capitalization of $559.18million.

Equities researchers at Roth Capital started coverage on shares of Concert Pharmaceuticals, Inc (NASDAQ:CNCE) in a research report issued on Thursday. The firm set a “buy” rating and a $28.00 price target on the stock. Roth Capital’s price target indicates a potential upside of 216.74% from the company’s current price. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)’s stock on June 12, 2014 reported a increase of 8.61% to the closing price of $9.46. Its fifty two weeks range is $7.12 -$16.26. The total market capitalization recorded $169.33million. The overall volume in the last trading session was 203.53K shares. In its share capital, CNCE has 17.90million outstanding shares.

Analysts at Aegis started coverage on shares of Recro Pharma Inc (NASDAQ:REPH) in a research report issued to clients and investors on Thursday. The firm set a “buy” rating and a $40.00 price target on the stock. Aegis’ price target points to a potential upside of 449.45% from the company’s current price. On Thursday, shares of Recro Pharma Inc (NASDAQ:REPH) advanced 6.46% to close the day at $7.75. Company monthly performance is recorded as 24.00%.  Recro Pharma Inc (NASDAQ:REPH) quarterly revenue growth is -6.40%.

Relypsa Inc (NASDAQ:RLYP) was the recipient of a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 963,019 shares, a growth of 52.1% from the April 30th total of 633,135 shares, StockRatingsNetwork reports. Currently, 4.1% of the shares of the company are sold short. Based on an average daily volume of 195,785 shares, the short-interest ratio is currently 4.9 days. Relypsa Inc (NASDAQ:RLYP) stock performance was 5.44% in last session and finished the day at $23.46. Traded volume was 222,277.00million shares in the last session and the average volume of the stock remained 249.64K shares.